Michael Bergman1, Angela Chetrit2, Jesse Roth3, Ram Jagannathan4, Mary Sevick4, Rachel Dankner5. 1. NYU School of Medicine, Department of Medicine, Division of Endocrinology and Metabolism, NYU Langone Diabetes Prevention Program, 530 First Avenue, Schwartz East, Suite 5E, New York, NY 10016, USA. Electronic address: michael.bergman@nyumc.org. 2. Unit for Cardiovascular Epidemiology, The Gertner Institute for Epidemiology and Health Policy Research, Sheba Medical Center, Tel Hashomer 52621, Israel. 3. The Feinstein Institute for Medical Research, Manhasset, North Shore, New York 11030, USA. 4. NYU School of Medicine, Department of Population Health, Division of Health Behavior Change, New York, NY 10016, USA. 5. Unit for Cardiovascular Epidemiology, The Gertner Institute for Epidemiology and Health Policy Research, Sheba Medical Center, Tel Hashomer 52621, Israel; The Feinstein Institute for Medical Research, Manhasset, North Shore, New York 11030, USA; Sackler Faculty of Medicine, School of Public Health, Department of Epidemiology and Preventive Medicine, Tel Aviv University, Ramat Aviv, Tel Aviv 69978, Israel.
Abstract
AIMS: The present study assessed the longitudinal association of an elevated 1-h plasma glucose [1-h-PG >8.6mmol/l (155mg/dl)] with and without impaired glucose tolerance [IGT; 2-h-PG 7.8-11.0mmol/l (140-199mg/dl)] with cumulative incident of diabetes and prediabetes over 24years in a non-diabetic cohort. METHODS: From 1979 to 1984, 1970 non-diabetic men and women completed an oral glucose tolerance test (OGTT), physical and biochemical measurements as well as a questionnaire related to lifestyle and medical background. During the years 2000-2004, 853 survivors of the original cohort were interviewed and re-examined for glycemic progression. RESULTS: Individuals with 1-h-PG >8.6mmol/l (155mg/dl) but with 2-h-PG <7.8mmol/l (140mg/dl) had a significantly elevated risk, compared to those with both 1-h-PG ⩽8.6mmol/l (155mg/dl) and 2-h-PG <7.8mmol/l (140mg/dl), for both diabetes [OR:4.35 (95%CI: 2.50-7.73)] and prediabetes outcomes [OR:1.87 (95%CI 1.09-3.26)], adjusted for sex and age, smoking, body mass index, blood pressure, fasting blood glucose and insulin. CONCLUSIONS: The risk for diabetes associated with a 1-h level >8.6mmol/l (155mg/dl) is increased and further worsened in the presence of IGT. Identifying individuals at risk with a 1-h-PG glucose level during an OGTT is recommended.
AIMS: The present study assessed the longitudinal association of an elevated 1-h plasma glucose [1-h-PG >8.6mmol/l (155mg/dl)] with and without impaired glucose tolerance [IGT; 2-h-PG 7.8-11.0mmol/l (140-199mg/dl)] with cumulative incident of diabetes and prediabetes over 24years in a non-diabetic cohort. METHODS: From 1979 to 1984, 1970 non-diabeticmen and women completed an oral glucose tolerance test (OGTT), physical and biochemical measurements as well as a questionnaire related to lifestyle and medical background. During the years 2000-2004, 853 survivors of the original cohort were interviewed and re-examined for glycemic progression. RESULTS: Individuals with 1-h-PG >8.6mmol/l (155mg/dl) but with 2-h-PG <7.8mmol/l (140mg/dl) had a significantly elevated risk, compared to those with both 1-h-PG ⩽8.6mmol/l (155mg/dl) and 2-h-PG <7.8mmol/l (140mg/dl), for both diabetes [OR:4.35 (95%CI: 2.50-7.73)] and prediabetes outcomes [OR:1.87 (95%CI 1.09-3.26)], adjusted for sex and age, smoking, body mass index, blood pressure, fasting blood glucose and insulin. CONCLUSIONS: The risk for diabetes associated with a 1-h level >8.6mmol/l (155mg/dl) is increased and further worsened in the presence of IGT. Identifying individuals at risk with a 1-h-PG glucose level during an OGTT is recommended.
Authors: Quinn Dufurrena; Farhad M Amjad; Philipp E Scherer; Louis M Weiss; Jyothi Nagajyothi; Jesse Roth; Herbert B Tanowitz; Regina Kuliawat Journal: Parasitol Res Date: 2016-12-24 Impact factor: 2.289
Authors: Michael Bergman; Ram Jagannathan; Martin Buysschaert; Jose Luis Medina; Mary Ann Sevick; Karin Katz; Brenda Dorcely; Jesse Roth; Angela Chetrit; Rachel Dankner Journal: Endocrine Date: 2017-01-25 Impact factor: 3.633
Authors: Marissa J Kilberg; Saba Sheikh; Darko Stefanovski; Christina Kubrak; Diva D De Leon; Denis Hadjiliadis; Ronald C Rubenstein; Michael R Rickels; Andrea Kelly Journal: J Cyst Fibros Date: 2019-08-08 Impact factor: 5.482
Authors: Kannan Kasturi; Anthony U Onuzuruike; Shwetha Kunnam; Lauren B Shomaker; Jack A Yanovski; Stephanie T Chung Journal: Pediatr Diabetes Date: 2018-12-27 Impact factor: 4.866
Authors: Adam Hulman; Unjali P Gujral; K M Venkat Narayan; Rajendra Pradeepa; Deepa Mohan; Ranjit Mohan Anjana; Viswanathan Mohan; Kristine Færch; Daniel R Witte Journal: Diabetes Res Clin Pract Date: 2017-02-17 Impact factor: 5.602
Authors: M L Marcovecchio; M Bagordo; E Marisi; T de Giorgis; V Chiavaroli; F Chiarelli; A Mohn Journal: J Endocrinol Invest Date: 2017-03-01 Impact factor: 4.256
Authors: Michael Bergman; Muhammad Abdul-Ghani; Ralph A DeFronzo; Melania Manco; Giorgio Sesti; Teresa Vanessa Fiorentino; Antonio Ceriello; Mary Rhee; Lawrence S Phillips; Stephanie Chung; Celeste Cravalho; Ram Jagannathan; Louis Monnier; Claude Colette; David Owens; Cristina Bianchi; Stefano Del Prato; Mariana P Monteiro; João Sérgio Neves; Jose Luiz Medina; Maria Paula Macedo; Rogério Tavares Ribeiro; João Filipe Raposo; Brenda Dorcely; Nouran Ibrahim; Martin Buysschaert Journal: Diabetes Res Clin Pract Date: 2020-06-01 Impact factor: 5.602